

# Advances in ENZYME REGULATION

Volume 22

*Proceedings of the Twenty-Second Symposium on Regulation of Enzyme  
Activity and Synthesis in Normal and Neoplastic Tissues  
held at Indiana University School of Medicine  
Indianapolis, Indiana  
October 3 and 4, 1983*

*Edited by*  
**GEORGE WEBER**  
*Indiana University School of Medicine  
Indianapolis, Indiana*

*Technical editor*  
*Catherine E. Forrest Weber*



PERGAMON PRESS  
OXFORD · NEW YORK · TORONTO  
SYDNEY · PARIS · FRANKFURT

U.K.	Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, England
U.S.A.	Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, New York 10523, U.S.A.
CANADA	Pergamon Press Canada Ltd., Suite 104, 150 Consumers Road, Willowdale, Ontario M2J 1P9, Canada
AUSTRALIA	Pergamon Press (Aust.) Pty. Ltd., P.O. Box 544, Potts Point, N.S.W. 2011, Australia
FRANCE	Pergamon Press SARL, 24 rue des Ecoles, 75240 Paris, Cedex 05, France
FEDERAL REPUBLIC OF GERMANY	Pergamon Press GmbH, Hammerweg 6, D-6242 Kronberg-Taunus, Federal Republic of Germany

---

Copyright © 1984 Pergamon Press Ltd.

*All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, electrostatic, magnetic tape, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publishers.*

First edition 1984

Library of Congress Catalog Card No. 63-19609

ISBN 0 08 031498 8  
ISSN 0065-2571

*Printed in Great Britain by A. Wheaton & Co. Ltd., Exeter*

Advances in  
**ENZYME REGULATION**

Volume 22

# QUANTITATIVE ANALYSIS OF DOSE-EFFECT RELATIONSHIPS: THE COMBINED EFFECTS OF MULTIPLE DRUGS OR ENZYME INHIBITORS

TING-CHAO CHOU\* and PAUL TALALAY†

\*Laboratory of Pharmacology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, and †Department of Pharmacology and Experimental Therapeutics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

## INTRODUCTION

The quantitative relationship between the dose or concentration of a given ligand and its effect is a characteristic and important descriptor of many biological systems varying in complexity from isolated enzymes (or binding proteins) to intact animals. This relationship has been analyzed in considerable detail for reversible inhibitors of enzymes. Such analyses have made assumptions on the mechanism of inhibition (competitive, noncompetitive, uncompetitive), and on the mechanism of the reaction for multi-substrate enzymes (sequential or ping-pong), and have required knowledge of kinetic constants (1-4). More recently, it has been possible to describe the behavior of such enzyme inhibitors by simple generalized equations that are independent of inhibitor or reaction mechanisms and do not require knowledge of conventional kinetic constants (i.e.  $K_m$ ,  $K_i$ ,  $V_{max}$ ) (5-8).

Our understanding of dose-effect relationships in pharmacological systems has not advanced to the same level as those of enzyme systems. Many types of mathematical transformations have been proposed to linearize dose-effect plots, based on statistical or empirical assumptions, e.g. probit (9, 10), logit (11) or power-law functions (12). Although these methods often provide adequate linearizations of plots, the slopes and intercepts of such graphs are usually devoid of any fundamental meaning.

## THE MEDIAN EFFECT PRINCIPLE

We demonstrate here the application of a single and generalized method for analyzing dose-effect relationships in enzymatic, cellular and whole animal systems. We also examine the problem of quantitating the effects of multiple inhibitors on such systems and provide definitions of summation of effects, and consequently of synergism and antagonism.

Since the proposed method of analysis is derived from generalized mass action considerations, we caution the reader that the analysis of dose-effect

data is concerned with basic mass-action characteristics rather than with proof of specific mechanisms. Nevertheless, it is convenient and intuitively attractive to analyze and normalize all types of dose-response results by a uniform method which is based on sound fundamental considerations that have physicochemical and biochemical validity in simpler systems. Our analysis is based on the median effect principle of the mass action law (5-8), and has already been shown to be simple to apply and useful in the analysis of complex biological systems (13).

#### *The Median Effect Equation*

The median effect equation (6, 8) states that:

$$f_a/f_u = (D/D_m)^m \quad (1)$$

where  $D$  is the dose,  $f_a$  and  $f_u$  are the fractions of the system affected and unaffected, respectively, by the dose  $D$ ,  $D_m$  is the dose required to produce the median effect (analogous to the more familiar  $IC_{50}$ ,  $ED_{50}$ , or  $LD_{50}$  values), and  $m$  is a Hill-type coefficient signifying the sigmoidicity of the dose-effect curve, i.e.,  $m = 1$  for hyperbolic (first order or Michaelis-Menten) systems. Since by definition,  $f_a + f_u = 1$ , several useful alternative forms of equation 1 are:

$$f_a/(1 - f_a) = [(f_a)^{-1} - 1]^1 = [(f_u)^{-1} - 1] = (D/D_m)^m$$

$$f_a = 1/[1 + (D_m/D)]^m$$

$$D = D_m[f_a/(1 - f_a)]^{1/m}$$

The median effect equation describes the behavior of many biological systems. It is, in fact, a generalized form of the enzyme kinetic relations of Michaelis-Menten (14) and Hill (15), the physical adsorption isotherm of Langmuir (16), the pH-ionization equation of Henderson and Hasselbalch (17), the equilibrium binding equation of Scatchard (18), and the pharmacological drug-receptor interaction (19). Furthermore, the median effect equation is directly applicable not only to primary ligands such as substrates, agonists, and activators, but also to secondary ligands such as inhibitors, antagonists, or environmental factors (5, 6).

When applied to the analysis of the inhibition of enzyme systems, the median effect equation can be used without knowledge of conventional kinetic constants (i.e.  $K_m$ ,  $V_{max}$  or  $K_i$ ) and irrespective of the mechanism of inhibition (i.e. competitive, noncompetitive or uncompetitive). Furthermore, it is valid for multisubstrate reactions irrespective of mechanism (sequential or ping-pong) (5-8).

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.